DOCSLIB.ORG

Bridging the Valley of Death: Improving the Commercialisation of Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bridging the Valley of Death: Improving the Commercialisation of Research House of Commons Science and Technology Committee Bridging the valley of death: improving the commercialisation of research Eighth Report of Session 2012–13 Volume II Additional written evidence Ordered by the House of Commons to be published 22 February 2012, 18 April 2012 and 25 April 2012 Published on 13 March 2013 by authority of the House of Commons London: The Stationery Office Limited Science and Technology Committee The Science and Technology Committee is appointed by the House of Commons to examine the expenditure, administration and policy of the Government Office for Science and associated public bodies. Current membership Andrew Miller (Labour, Ellesmere Port and Neston) (Chair) Jim Dowd (Labour, Lewisham West and Penge) Stephen Metcalfe (Conservative, South Basildon and East Thurrock) David Morris (Conservative, Morecambe and Lunesdale) Stephen Mosley (Conservative, City of Chester) Pamela Nash (Labour, Airdrie and Shotts) Sarah Newton (Conservative, Truro and Falmouth) Graham Stringer (Labour, Blackley and Broughton) David Tredinnick (Conservative, Bosworth) Hywel Williams (Plaid Cymru, Arfon) Roger Williams (Liberal Democrat, Brecon and Radnorshire) The following members were also members of the committee during the parliament: Gavin Barwell (Conservative, Croydon Central) Caroline Dinenage (Conservative, Gosport) Gareth Johnson (Conservative, Dartford) Gregg McClymont (Labour, Cumbernauld, Kilsyth and Kirkintilloch East) Stephen McPartland (Conservative, Stevenage) Jonathan Reynolds (Labour/Co-operative, Stalybridge and Hyde) Powers The Committee is one of the departmental Select Committees, the powers of which are set out in House of Commons Standing Orders, principally in SO No.152. These are available on the Internet via www.parliament.uk Publications The Reports and evidence of the Committee are published by The Stationery Office by Order of the House. All publications of the Committee (including press notices) are on the Internet at http://www.parliament.uk/science. A list of reports from the Committee in this Parliament is included at the back of this volume. The Reports of the Committee, the formal minutes relating to that report, oral evidence taken and some or all written evidence are available in printed volume(s). Additional written evidence may be published on the internet only. Committee staff The current staff of the Committee are: Dr Stephen McGinness (Clerk); Jessica Montgomery (Second Clerk); Xameerah Malik (Senior Committee Specialist); Victoria Charlton (Committee Specialist); Darren Hackett (Senior Committee Assistant); Julie Storey (Committee Assistant); Henry Ayi-Hyde (Committee Office Assistant); and Nick Davies (Media Officer). Contacts All correspondence should be addressed to the Clerk of the Science and Technology Committee, Committee Office, 7 Millbank, London SW1P 3JA. The telephone number for general inquiries is: 020 7219 2793; the Committee’s e- mail address is: [email protected]. List of additional written evidence Page 1 Roger Browne Ev w1 2 Plymouth University Ev w3 3 Professor Peter Dobson, Begbroke Science Park, University of Oxford Ev w6 4 Bournemouth University Ev w7 5 Scottish Lifesciences Association Ev w8 6 The University of Edinburgh Ev w10 7 Health Protection Agency Ev w12 8 Babraham Bioscience Technologies Ltd Ev w14 9 Frank J Morris Ev w15 10 United Kingdom Science Park Association Ev w16 11 Cambridge Enterprise Ltd Ev w17 12 RSPCA Ev w21 13 Mark A Phillips Ev w22 14 Engineering YES Ev w23 15 Simon Payne Ev w25 16 Groupe Intellex Ev w27 17 Professor Michael Ferguson Ev w?? 18 Dr Venketesh Dubey Ev w30 19 Yorkshire Cancer Research Ev w31 20 Professor R Charles Coombes and Professor Anthony G M Barrett Ev w?? 21 British Society of Plant Breeders Ev w33 22 The Royal Society of Edinburgh Ev w37 23 UK Innovation Research Centre and the Centre for Business Research Ev w42 24 Isis Innovation Ltd Ev w46 25 The University of Birmingham Ev w49 26 Geoff Lawton, Simon Campbell, John Dixon, Paul England, Peter Machin, and Alan Palmer Ev w52 27 Tokamak Solutions UK Ltd Ev w56 28 Dr Michael M Hopkins, SPRU, University of Sussex Ev w60 29 Society of Biology Ev w63 30 Plant Bioscience Limited Ev w69 31 Action on Hearing Loss Ev w71 32 Imperial Innovations Group plc Ev w75 33 Royal Society of Chemistry Ev w80 34 Drug Discovery Centre, Imperial College London Ev w83 35 The Publishers Association Ev w85 36 The Association of Independent Research and Technology Organisations (AIRTO) Ev w88 37 Midven Ev w92 38 The Academy of Medical Sciences Ev w95 39 Cambridge Environmental Research Consultants Ltd Ev w100 40 BP plc Ev w102 41 LGC Limited Ev w105 42 BioIndustry Association (BIA) Ev w109 43 Electronics Technology Network Ev w114 44 University College London Ev w128 45 Ian Phillips Ev w131 46 Plymouth Marine Laboratory Applications Ltd Ev w133 47 STFC Innovations Ltd Ev w135 48 The University of Oxford Ev w138 49 Smart Club for the East of England (SCEE) Ev w141 50 Smart Club for the East of England (SCEE) Committee Ev w142 51 Cancer Research UK Ev w143 52 Agricultural Biotechnology Council (abc) Ev w148 53 Institute of Physics Ev w153 54 UK Computing Research Committee Ev w156 55 National Farmers’ Union Ev w158 56 Ethical Medicines Industry Group Ev w163 57 Energy Technologies Institute (ETI) Ev w166 58 The Royal Society Ev w169 59 Golden Rice Ev w171 60 SETsquared Partnership Ev w173 61 BMT Group Ltd Ev w175 62 Campaign for Science and Engineering (CaSE) Ev w177 63 Novartis Ev w180 64 Met Office Ev w183 65 Association of Medical Research Charities Ev w185 66 Professor Michael Ferguson Ev w192 67 Professor Anthony G M Barrett and Professor R Charles Coombes Ev w194 68 Sir Gregory Winter FRS Ev w196 69 ADS Ev w198 70 Professor William O'Neill cobber Pack: U PL: COE1 [SO] Processed: [11-03-2013 14:03] Job: 021047 Unit: PG01 Source: /MILES/PKU/INPUT/021047/021047_w069_steve_PValley 96 William O'Niell.xml Science and Technology Committee: Evidence Ev w1 Written evidence Written evidence submitted by Roger Browne, MD Futurology Limited Summary There is a gap/valley of death. A key reason is the different skill sets, behaviour and even values of those conducting research & development and those who have the entrepreneurial skills to spot a market opportunity and exploit it. Those developing the “new” are often so in love with their creation they assume the world will welcome “their baby” with open arms. Those with the skills to move from prototype to (say) bulk production, those able to promote the benefits of the offering, those able to kick open the doors of opportunity, are often not recruited to the team. Those working on products, services or processes that will address Climate Change issues face even greater difficulties, since they will often need to change people’s behaviour as well as have their new offering accepted. Picking winners is a most difficult task—but often there is no plan or approaches to catch proposals that are not funded but that emerge as strong opportunities sometime later. Work is already underway—The EU funded Climate KIC project—to increase the involvement of business and to help understand how to change behaviours. The focus of this work must not just be on research institutes, we need to address those best able (?) to commercialise the “new”—existing businesses. This is not a sprint but a marathon and a great deal of work will be required to change UK businesses so they are truly innovative and seek and welcome the “new”. 1. The gap In my experience there is a large gap between the “new” and the “existing”, there always has been and it hasn’t recently gone away! The gap exists whether the “new” is a new product, a new process, a new service or a new business model. It exists because there are always many who resist change, particularly those who fear that the “new” will encroach on their territory and negatively affect their income. The best example I have heard recently of this phenomenon, came from Prof. Fred Steward, Professor of Innovation and Sustainability, Policy Studies Institute, University of Westminster. Professor Steward, speaking recently in Brussels, pointed out that the wooden shipbuilders and sail makers [amongst many others!] did not welcome the advent of steam power and iron ships! 2. A problem compounded The facts that the existing providers often display “vested interest” mode, and that the prospective market is slow to react/accept the new offering both compound the problem. The problem is then further compounded because those researching/designing/developing the “new” are commonly good at technical issues but not so good in other areas—key areas such as finance, marketing and commercialisation tasks. Those at the research/design “front end” are often so in love with their “baby” that they believe that the market will immediately grasp the “new” and “beat a path to their door”. Seldom is this true. Vested interests abound! There is also an enormous amount of work to get a product from the drawing board or lab to market! A task that is often under-estimated and not considered until far too late in the development life cycle. 3. Skill sets Those at the front end often lack the entrepreneurial skills needed to understand the market needs [and more importantly the market “wants”] and the force of character to overcome the many hurdles between the research lab and profitable trading. Perhaps more importantly the fail to see the need to engage people to the team that do have these skills. Outlining the problems that are likely to occur unless a complete team is assembled; isn’t an easy task and the messenger is sometimes at risk!” A few individuals do have a complete skill set—perhaps Sir James Dyson is the best example of someone who seems equally at home in the laboratory, as the board room, as the City of London.
Load more

Recommended publications
  • Science Committee
    SCIENCE COMMITTEE TERMS OF REFERENCE (Approved by the Board on 19 December 2016) (Established from 1 January 2017. Last updated on 6 May 2021) Role The Committee supports the Board in its understanding of the key strategic themes, upon which the Company’s R&D strategy is based, and of any external transactions, by performing in depth reviews of the underlying scientific assumptions to give the Board technical assurance. It also undertakes more in depth risk oversight of R&D related risks. Membership Chairman Dr Jesse Goodman Members Charles Bancroft Dr Laurie Glimcher Generally in Company Chairman attendance Chief Executive Officer (“CEO”) at each meeting: Chief Scientific Officer and President R&D (“CSO”) President, Global Vaccines In attendance as Independent senior external scientific adviser(s) as required: Chief Financial Officer Chief Medical Officer SVP, Head of Audit & Assurance SVP, Global Ethics & Compliance Other Company executives Secretary Company Secretary Constitution 1. The Board has established a Committee of the Board known as the Science Committee (the "Committee"). Membership 2. The Committee shall comprise a minimum of three Non-Executive Directors of the Company appointed by the Board. 3. The Committee Chairman shall be a Non-Executive Director, designated as a Scientific and Medical Expert, appointed by the Board following receipt of a proposal from the Nominations 1 Science Committee Terms of Reference & Corporate Governance Committee. 4. The Committee Chairman, in collaboration with the CSO and CEO, shall review membership of the Committee annually, as part of the annual performance evaluation of the Committee. Quorum 5. The quorum shall be three members.
    [Show full text]
  • Biggar Economics
    BiGGAR Economics 4 OXFORD: THE UNIVERSITY AND THE CITY This section provides background to the University of Oxford as well as describing the economic context in which it operates. 4.1 University of Oxford The University of Oxford is the oldest university in the English-speaking world, with teaching taking place since 1096. It has played an important role in history and culture for centuries, educating several of the world's leading politicians and conducting research and scholarship that has revolutionised the world. In 2104/15 the collegiate University employed more than 17,620 staff, had a total income of £1.9 billion and more than 19,800 full-time students. The University’s aim is to lead the world in research and education in ways that benefit society on a national and global scale. As an internationally renowned centre for teaching and research, the University of Oxford is consistently ranked among the foremost universities in the world: the University is ranked first in the world in the Times Higher Education University Rankings6; the University is ranked first in the UK for research council income; in the disciplinary tables, the University was ranked for the sixth year running, first in the world for Clinical, Pre-Clinical and Health subjects; ranked second in the world and first in the UK for Social Sciences; placed third in the world and first in the UK for Arts and Humanities, Business and Economics, Computer Science, and Engineering and Technology; third in the world and second in the UK for Life Sciences; and sixth in the world and second in the UK for Physical Sciences.
    [Show full text]
  • Notice of Meeting for the Eighteenth Annual General Meeting (AGM) of Glaxosmithkline Plc
    GlaxoSmithKline plc Image HIV virus Notice of Annual General Meeting Thursday 3 May 2018 at 2.30pm This document is important and requires your immediate attention. If you are in any doubt as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser immediately. If you have sold or otherwise transferred all of your shares, please pass this document, together with the accompanying documents, to the purchaser or transferee, or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares. 2 29 March 2018 To the holders of the company’s Ordinary Shares and American Depositary Shares. Dear Shareholder, Annual General Meeting 2018 I am pleased to enclose the Notice of Meeting for the eighteenth Annual General Meeting (AGM) of GlaxoSmithKline plc. The AGM will be held on Thursday 3 May 2018 at 2.30pm at the QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE. If you will not be attending, you may appoint a proxy by completing and returning the enclosed proxy form. Alternatively, you may appoint a proxy electronically via www.shareview.co.uk, www.sharevote.co.uk or, if you hold your shares in CREST, via the CREST system. Notice of your appointment of a proxy should reach the company’s registrar, Equiniti, by 2.30pm on Tuesday 1 May 2018. If you hold your shares through a nominee service, please contact the nominee service provider regarding the process for appointing a proxy. Included in the business of the AGM are resolutions to receive and adopt the Directors’ Report and the Financial Statements for 2017, to approve the Annual report on remuneration for the year ended 31 December 2017 and to confirm the appointment of Deloitte LLP as the company’s auditors.
    [Show full text]
  • Resolution Notice (PDF: 67KB)
    NOTICE: This is a translation of a notice in Japanese issued on June 23, 2017 and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail. Securities code: 4536 June 23, 2017 RESOLUTION NOTICE OF THE 105TH ANNUAL GENERAL MEETING OF SHAREHOLDERS OF SANTEN PHARMACEUTICAL CO., LTD. Dear Shareholder: We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 105th Annual General Meeting of Shareholders of the Company that was held today. Reports: 1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 105th Business Term (April 1, 2016 to March 31, 2017) 2. Reports on the Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 105th Business Term (April 1, 2016 to March 31, 2017) As regards the items set forth above, the contents thereof were reported. Resolved Items: Proposal No. 1: Appropriation of Surplus As regards this item, the term-end dividends of profits were resolved to be JPY 13 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 26 per share. Proposal No. 2: Appointment of Seven (7) Directors As regards this item, Akira Kurokawa, Takeshi Ito, Akihiro Tsujimura, Shigeo Taniuchi, Takayuki Katayama, Kanoko Oishi and Yutaro Shintaku were appointed as per the original proposal; each of them assumed their respective offices. Takayuki Katayama, Kanoko Oishi and Yutaro Shintaku are Outside Directors.
    [Show full text]
  • Download a PDF of Our Community Brochure
    Engagement with the communities of Oxford and Oxfordshire Did you know? St Giles’ Fair began as the parish feast of St Giles, first recorded in 1624. From the 1780s it became a toy fair, with general amusements for children. In the next century its focus shifted towards adults, with entertainment, rides and stalls. In the late 1800s there were calls for the fair to be stopped on the grounds that it encouraged rowdy behaviour. During Victorian times engineering advances brought the forerunners of today’s rides. Today the huge pieces of machinery fill St Giles’ with sparkling lights for a few days each year, and whizz within feet of ancient college buildings. The stone heads around the Sheldonian Theatre now number thirteen (there were originally fourteen, but one was removed to make way for the adjoining Clarendon Building.) It is not known what they were intended to represent – they might be gods, wise men, emperors or just boundary markers. The original heads were made by William Byrd and put up in 1669. Did you Replacements put up in 1868 were made in poor stone, know? which crumbled away; in 1972 the current set, carved by Michael Black of Oxford, were erected. More on page 4 STARGAZING AND SPIN-OUTS PAGE 1 Contents 2 Introduction from the Vice-Chancellor 3 Foreword from the Chair of the Community Engagement Group 5 Part 1: Part of the fabric of the city Part of the fabric 6 800 years of history of the 8 Economic impact city 9 Science Parks 1 0 Saïd Business School 11 Oxford University Press PART 1 PART 1 2 The built environment 13
    [Show full text]
  • West of England Strategic Economic Plan 2015-2030 01 Contents
    WE ARE A PARTNERSHIP FOR GROWTH EMBRACING GROWTH DEAL NEGOTIATIONS FOR 2015-2021 WEST OF ENGLAND STRATEGIC ECONOMIC PLAN 2015-2030 01 CONTENTS Curriculum Vitae: Knowledge, Innovation, Quality of Life 03 Forewords by James Dyson and Colin Skellett 04 1 The West of England Strategic Economic Plan 06 2 The City Region of Choice for a sustainable future 18 3 Economic Strategy 24 4 Local Growth Fund Deal Negotiations 31 5 Using our Levers of Growth 62 5.1 People – Knowledge Economy, Skills & Social Inclusion 63 5.2 Place & Infrastructure 70 5.3 Investment & Promotion 78 5.4 SME Business Support 82 6 Implementation Plan 88 7 Delivery Plan 96 8 Evaluation Plan 106 Appendices 112 Appendix 1: Six Year Plan for the Local Growth Fund 114 Appendix 2: FE Capital Projects – a breakdown of individual proposals 116 Appendix 3: Deadweight and displacement calculations 118 Appendix 4: Pipeline of interventions for the Local Growth Fund 120 3-6 year programme Appendix 5: The Process to identify Interventions for the 124 Local Growth Fund Appendix 6: Shared Priority Investment Maps & Key 126 Appendix 7: Full Business Case Template 138 Technical Supporting Documents available on the LEP website: www.westofenglandlep.co.uk/strategicplan 1 Outline Business Cases for the Local Growth Fund current 2 year programme 2 LEP Sector Prospectus 3 Equality Impact Assessment CuRRICULUM VITAE: KNOWLEDGE, INNOVATION, QUALITY OF LIFE 02|03 CuRRICULUM VITAE KNOWLEDGE, INNOVATION, QUALITY OF LIFE • Over one million people and growing Knowledge Quality of Life • An economy worth
    [Show full text]
  • Enterprising Universities Using the Research Base to Add Value to Business
    Policy Report September 2010 Enterprising Universities Using the research base to add value to business 1100901_EnterprisingUniversities.indd00901_EnterprisingUniversities.indd A 009/09/20109/09/2010 115:025:02 The 1994 Group > The 1994 Group is established to promote excellence in university research and teaching. It represents 19 of the UK’s leading research-intensive, student focused universities. Around half of the top 20 universities in UK national league tables are members of the group. > Each member institution delivers an extremely high standard of education, demonstrating excellence in research, teaching and academic support, and provides learning in a research-rich community. > The 1994 Group counts amongst its members 12 of the top 20 universities in the Guardian University Guide 2011 league tables published on the 8th June 2010. 7 of the top 10 universities for student experience are 1994 Group Universities (2009 National Student Survey). In 17 major subject areas 1994 Group universities are the UK leaders achieving 1st place in their fi eld (THE RAE subject rankings 2008). 57% of the 1994 Group's research is rated 4* 'world- leading' or 3* 'internationally excellent' (RAE 2008, HEFCE). > The 1994 Group represents: University of Bath, Birkbeck University of London, Durham University, University of East Anglia, University of Essex, University of Exeter, Goldsmiths University of London, Institute of Education University of London, Royal Holloway University of London, Lancaster University, University of Leicester, Loughborough
    [Show full text]
  • POSITION PROFILE: CHIEF SCIENTIFIC OFFICER the Chief
    POSITION PROFILE: CHIEF SCIENTIFIC OFFICER The Chief Scientific Officer (CSO) at the Gulf of Maine Research Institute (GMRI) will lead a multidisciplinary team of world-class scientists conducting marine research to better understand and steward the Gulf of Maine ecosystem—from its physical dynamics to its human communities. The CSO will apply a systems approach to develop scientific priorities, conduct research, pioneer collaborative solutions to global ocean challenges, and help shape the conversation around climate change and ecosystem sustainability at the local, national, and international levels. GMRI infuses its research findings into the policy arena and designs solutions with fishermen, aquaculturists, and seafood businesses to sustain fishery resources, harvest them responsibly, and market them as premium quality food. GMRI nurtures emerging leaders in communities that depend on the sea. GMRI's education programs cultivate science literacy and build a foundation of collaborative problem-solving among our next generation of leaders, scientists, citizens, and stewards. Each year, GMRI serves over 25,000 stakeholders from Cape Cod to Nova Scotia. Working closely with the leaders of GMRI’s other core program areas (Education and Community) and cross-cutting programs (Climate Center and Business Development), the CSO will facilitate integration of research into GMRI’s strategic plan to ensure that our Research Team’s activities are synergistic with, and deepen the impacts of, adjacent program areas. The CSO will also work closely with our Development Team to cultivate and steward key donors (private foundations, individuals, corporations) supporting both GMRI’s science capacity and general operations. The CSO is a key leadership position and serves a vital role on GMRI’s Management Team.
    [Show full text]
  • Mcgill's Dobson International Startup Tour
    McGILL’S DOBSON INTERNATIONAL STARTUP TOUR March 18-19, 2021 NORTH AMERICA – WEST COAST UPPORT EMERGING BUSINESSES TO ACCELERATE THEIR RAPID DEVELOPMENT Québec abounds in talented individuals who dare to initiate and innovate. More than 2000 startups with strong growth potential are operating in different areas of activity. They are noteworthy for their original business models and bold reliance on new technologies. Ensuring the development of this thriving ecosystem is essential to maintain the Québec economy’s competitiveness. The Québec government is delighted to encourage the Dobson Centre for Entrepreneurship at McGill University in conjunction with the McGill International Startup Tour. I would especially like to emphasize the multidisciplinarity of the sectors covered and the scientific relations that have developed between major Québec universities. Moreover, this project is brilliantly helping to better match research and its practical LUCIE LECOURS applications through the marketing of products stemming from university research. Ministre déléguée à The tour will raise the international profile l’Économie of Québec innovations and is another example that shows that our knowledge-based economy creates collective wealth. I salute all the participants for their to commitment to showcasing Québec ingenuity and creativity the world over. Best wishes to the innovative young entrepreneurs for a successful tour! Lucie Lecours Minister for Economy CHERS ENTREPRENEURS, C’est avec grand plaisir que les représentations du Québec à Los Angeles et Silicon Valley s’associent au volet Amérique de la tournée internationale des jeunes pousses organisée par le Centre Dobson de l’Université McGill. Plus que jamais, les entrepreneurs qui veulent réussir doivent être audacieux et innovants et la côte ouest américaine offre de multiples opportunités pour les entrepreneurs dynamiques.
    [Show full text]
  • Inozyme Pharma Appoints Yves Sabbagh, Ph.D., As Senior Vice President and Chief Scientific Officer – Dr
    Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer – Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs – – Company Announces Retirement of David Thompson, Ph.D. – – Company to Open New Laboratory Space to Increase R&D Capabilities – BOSTON, Oct. 13, 2020 [GLOBE NEWSIRE] – Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced the appointment of Yves Sabbagh, Ph.D., as senior vice president and chief scientific officer, and the retirement of David Thompson, Ph.D., Inozyme’s former chief scientific officer. Dr. Sabbagh brings to Inozyme more than 20 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates. Dr. Sabbagh will be responsible for expanding Inozyme’s proprietary pipeline by identifying and developing new therapeutics for monogenic and non-genetic diseases of abnormal mineralization. “Yves is an accomplished and well-regarded scientist in the areas of renal, bone and mineral research and brings to Inozyme extensive management experience leading teams developing highly innovative drug candidates,” said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. “I want to express my deep appreciation for David’s extensive contributions over the last several years. He has been instrumental in establishing the research group at Inozyme and our portfolio of indications for INZ-701.
    [Show full text]
  • Press Release
    Press Release Astellas Announces Management Structure TOKYO, February 4, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced the following Executive Comittee Standing Members effective from April 1, 2021. Executive Committee*1 Standing Members (as of April 2021) Under Corporate Strategic Plan 2018, Astellas highlights “Evolving How We Create VALUE with Focus Area Approach” as one of its strategic goals. The goal of the Focus Area approach is to create innovative pharmaceuticals for diseases with high unmet medical needs by identifying unique combinations of biologies with clear disease relevance and versatile modalities / technologies. Chief Scientific Officer (CScO) is newly assigned for accelerating the Focus Area approach by strengthening research activities. Yoshitsugu Shitaka, who is currently the President of Astellas Institute for Regenerative Medicine and has contributed significantly to the development of the cell therapy, will be appointed to CScO, and will also serve as the President, Drug Discovery Research. Furthermore, Chief Business Officer (CBO) is newly assigned to lead and supervise the execution of Corporate Strategic Plan starting in Fiscal Year 2021. Percival Barretto-Ko, who has demonstrated a strong track record of robust leadership as President of United States Commercial will be appointed to CBO. Title Name New Representative Director, Kenji Yasukawa President and Chief Excecutive Officer (CEO) Representative Director, Naoki Okamura Corporate Executive Vice President, Chief Strategy Officer (CStO) and Chief Financial Officer (CFO) Chief Administrative Officer (CAO) and Fumiaki Sakurai Chief Ethics & Compliance Officer (CECO) Chief Medical Officer (CMO) Bernhardt Zeiher Chief Commercial Officer (CCO) Yukio Matsui Chief Scientific Officer (CScO) Yoshitsugu Shitaka ✔ Chief Business Officer (CBO) Percival Barretto-Ko ✔ General Counsel Catherine Levitt 1 *1 Executive Committee: an organization that discusses significant matters of management across Astellas.
    [Show full text]
  • The British Innovation Fund Investing in the Best of UK University Venturing
    The British Innovation Fund Investing in the Best of UK University Venturing For discussion purposes with Professional Investors only 2Q 2020 BRITISH INNOVATION FUND EXECUTIVE SUMMARY Key Areas of Specialty: Agricultural Bio- Technologies technology The BIF has been backed by some of The BIF is managed in the leading local The British Innovation partnership with government pension Deep Tech Life Sciences Milltrust International LLP Fund (BIF) is an schemes in the and Milltrust Agricultural AIFMD-compliant United Kingdom patient capital venture Investments, and supported by an capital fund investing in cutting edge spin- Alternative Advisory team of Nano Tech investment specialists outs emanating from Protein and agricultural and leading UK university research. scientific experts. 2 INVESTMENT PREMISE “Exploration is the engine that drives innovation. Innovation drives economic growth.” - Edith Widder 3 INVESTMENT PREMISE A BRIEF HISTORY OF BRITISH INNOVATION Sir Isaac Newton, PRS 25 December 1642 – 20 March 1726 Sir Alexander Fleming, FRS FRSE FRCS English mathematician, physicist, astronomer, 6 August 1881 – 11 March 1955 theologian, and author widely recognised as one of the Scottish biologist, physician, micro-biologist, most influential scientists of all time and as a key figure and pharmacologist. Inventor of Penicillin. in the scientific revolution. Edward Jenner, FRS FRCPE FLS John Logie Baird, FRSE 17 May 1749 – 26 January 1823 13 August 1888 – 14 June 1946 English physician who was a contributor to the Scottish engineer and innovator. One of the inventors of development of the smallpox vaccine. the mechanical television. Michael Faraday, FRS 22 September 1791 – 25 August 1867 John Adrian Shepherd-Barron, OBE English scientist who contributed to the study 23 June 1925 – 15 May 2010 of electromagnetism and electrochemistry.
    [Show full text]